Research Articles | Page 23 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map Dec 2020 Hematology. American Society of Hematology. Education Program Myelodysplastic Syndromes (MDS)
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab Aug 2020 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Oct 2023 Oncologist Myelodysplastic Syndromes (MDS)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Apr 2023 The Oncologist Myelodysplastic Syndromes (MDS)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Apr 2023 The Oncologist Myelodysplastic Syndromes (MDS)
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria Jun 2023 Blood Advances Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Mar 2021 The New England Journal of Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes Sep 2019 Clinical Cancer Research: an official Journal of the American Association of Cancer Research Myelodysplastic Syndromes (MDS)
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria Aug 2023 Haematologica Paroxysmal Nocturnal Hemoglobinuria (PNH)